Pharmacological Reports · 8 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This retrospective study evaluated the safety of a non-standard 3-day intravenous methylprednisolone regimen for Graves' orbitopathy. The central result was that the regimen was associated with mild side effects, primarily hyperglycemia and elevated liver enzymes, but no serious adverse events like death or liver damage.
This retrospective single-centre study assessed the safety profile of a non-standard regimen of 1 g intravenous methylprednisolone administered for three consecutive days in 161 patients with active, moderate-to-severe or sight-threatening Graves' orbitopathy. Results showed mild side effects occurred in 71% of hospitalizations, with hyperglycemia (n=95) and elevated aminotransferases (n=31) being most common. No serious complications such as sudden deaths, liver damage, or thrombosis were observed. Risk factors for elevated aminotransferases included smoking and disease duration over 12 months. The authors conclude the regimen is relatively safe but requires monitoring in specialized centres. Limitations include the retrospective design and potential missing data.
